Microalgae Extracellular Vesicles (MEV) as Delivery Systems.
WHAT WE DO
As a Contract Development and Manufacturing Organization, we develop industry-scale processes for the manufacture of microalgae extracellular vesicles (MEV) for multiple purposes; non-GMP and cGMP-compliant.
Our current manufacturing capacity gauges between 500 and 600L per MEV batch.
As a Contract Development and Manufacturing Organization, we develop industry-scale processes for the manufacture of microalgae extracellular vesicles (MEV).
Our processes are meant for multiple purposes:
non-GMP
and cGMP-compliant.
Our current manufacturing capacity gauges between 500 and 600L per MEV batch.
This capacity is fully operational for Clinical trial Phases I and II.
AGS-M has initiated the construction work for its future Pilot Manufacturing Unit, dedicated to the production of MEVs.
Site’s surface area = xx
GMP quality
Construction and implementation in partnership with XX
Financing of XM€
Localisation XX
PMU in conditions to deliver the first batch in time for the filing of AGS’ first IND (Investigation on New Drug) to the FDA, in early 2026.
>> link to PIPELINE AGS Therapeutics
AGS-M is currently producing and delivering non-GMP batches of MEVs as part as its collaborations programs.
AGS-M has initiated the construction work for its future Pilot Manufacturing Unit, dedicated to the production of MEVs.
Site’s surface area = xx
GMP quality
Construction and implementation in partnership with XX
Financing of XM€
Localisation XX
PMU in conditions to deliver the first batch in time for the filing of AGS’ first IND (Investigation on New Drug) to the FDA, in early 2026.
>> link to PIPELINE AGS Therapeutics
AGS-M has initiated the construction work for its future Pilot Manufacturing Unit, dedicated to the production of MEVs.
Site’s surface area = xx
GMP quality
Construction and implementation in partnership with XX
Financing of XM€
Localisation XX
PMU in conditions to deliver the first batch in time for the filing of AGS’ first IND (Investigation on New Drug) to the FDA, in early 2026.
>> link to PIPELINE AGS Therapeutics
AGS-M has initiated the construction work for its future Pilot Manufacturing Unit, dedicated to the production of MEVs.
Site’s surface area = xx
GMP quality
Construction and implementation in partnership with XX
Financing of XM€
Localisation XX
PMU in conditions to deliver the first batch in time for the filing of AGS’ first IND (Investigation on New Drug) to the FDA, in early 2026.
>> link to PIPELINE AGS Therapeutics
